Table 3.
Biochemical Variables Among Women Receiving a Single Oral Megadose of VD3 Supplementation (n=14) or the Placebo (n=15) in the Moments Before and After 4-Week Intervention
| Variables | Placebo | VD3 | p-value |
|---|---|---|---|
| Calcium (mg/dL) | |||
| Before | 9.0 (8.8–9.2) | 8.9 (8.7–9.1) | 0.715 |
| Week 4 | 9.5 (9.3–9.7)* | 9.4 (9.2–9.6)* | 0.506 |
| PTH (pg/mL) | |||
| Before | 43.9 (29.7–78.9) | 43.9 (35.2–52.6) | 0.898 |
| Week 4 | 54.8 (45.2–64.4)* | 42.4 (16.7–90.6) | 0.049 |
| AST (IU/L) | |||
| Before | 21.5 (18.2–24.7) | 21.6 (19.0–24.1) | 0.957 |
| Week 4 | 18.9 (12.0–48.0) | 16.1 (14.2–18.1)* | 0.441 |
| ALT (IU/L)# | |||
| Before | 25.0 (16.0–42.0) | 19.5 (11.0–46.0) | 0.099 |
| Week 4 | 24.0 (12.0–72.0) | 16.0 (11.0–31.0)* | 0.013 |
| Creatinine (mg/dL) | |||
| Before | 0.82 (0.75–0.89) | 0.79 (0.73–0.85) | 0.465 |
| Week 4 | 0.64 (0.59–0.69)* | 0.69 (0.64–0.74)* | 0.179 |
| FG (mg/dL)# | |||
| Before | 95 (82–157) | 89.5 (77–179) | 0.690 |
| Week 4 | 96 (89–170) | 94 (83–167) | 0.370 |
Notes: *p-value shows a significant difference between moments (p<0.05). #Non-parametric data
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; FG, fasting glucose. PTH, parathyroid hormone.